Macrophage inflammatory protein-2 (MIP-2)/CXCR2 blockade attenuates acute graft-versus-host disease while preserving graft-versus-leukemia activity

Biochemical and Biophysical Research Communications

Volumn 426, Issue 4, 2012, Pages 558-564

  Cho, Kyung Ah ^a   Woo, So Youn ^a   Park, Yoon Shin ^a   Park, Min Hwa ^a   Ryu, Kyung Ha ^a  

^a Ewha Womans University School of Medicine   (South Korea)

Author keywords

Bone marrow transplantation; CXCR2; Graft versus host disease; Graft versus leukemia; MIP 2

Indexed keywords

BUSULFAN; CHEMOKINE RECEPTOR CXCR2; CHEMOKINE RECEPTOR CXCR2 ANTAGONIST; CYCLOPHOSPHAMIDE; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 23; KERATINOCYTE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 2; MACROPHAGE INFLAMMATORY PROTEIN 2 ANTIBODY; RECOMBINANT CYTOKINE; T CELL FACTOR PROTEIN; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; B CELL LEUKEMIA; CELL MIGRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HISTOPATHOLOGY; IMMUNOASSAY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; RECEPTOR UPREGULATION; SYMPTOM; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ANIMALS; BONE MARROW TRANSPLANTATION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOKINE CXCL2; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; MICE; MICE, INBRED BALB C; RECEPTORS, INTERLEUKIN-8B; T-LYMPHOCYTES;

MURINAE;

EID: 84867220572     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.126     Document Type: Article

References (27)

1. Yee G.C., McGuire T.R. Allogeneic bone marrow transplantation in the treatment of hematologic diseases. Clin. Pharm. 1985, 4:149-160.
2. Servais S., Baron F., Beguin Y. Allogeneic hematopoietic stem cell transplantation (HSCT) after reduced intensity conditioning. Transfus. Apher. Sci. 2011, 44:205-210.
3. Ghorashian S., Nicholson E., Stauss H.J. T cell gene-engineering to enhance GVT and suppress GVHD. Best Pract. Res. Clin. Haematol. 2011, 24:421-433.
4. Coghill J.M., Carlson M.J., Panoskaltsis-Mortari A., West M.L., Burgents J.E., Blazar B.R., Serody J.S. Separation of graft-versus-host disease from graft-versus-leukemia responses by targeting CC-chemokine receptor 7 on donor T cells. Blood 2010, 115:4914-4922.
5. Sadeghi B., Al-Hashmi S., Hassan Z., Rozell B., Concha H., Lundmark C., Gronvik K.O., Abedi-Valugerdi M., Hassan M. Expansion and activation kinetics of immune cells during early phase of GVHD in mouse model based on chemotherapy conditioning. Clin. Dev. Immunol. 2010, 2010:142943.
6. New J.Y., Li B., Koh W.P., Ng H.K., Tan S.Y., Yap E.H., Chan S.H., Hu H.Z. T cell infiltration and chemokine expression: relevance to the disease localization in murine graft-versus-host disease. Bone Marrow Transplant. 2002, 29:979-986.
7. Pelus L.M., Fukuda S. Chemokine-mobilized adult stem cells defining a better hematopoietic graft. Leukemia 2008, 22:466-473.
8. Markey K.A., Burman A.C., Banovic T., Kuns R.D., Raffelt N.C., Rowe V., Olver S.D., Don A.L., Morris E.S., Pettit A.R., Wilson Y.A., Robb R.J., Randall L.M., Korner H., Engwerda C.R., Clouston A.D., Macdonald K.P., Hill G.R. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood 2010, 115:122-132.
9. Heijmans-Antonissen C., Wesseldijk F., Munnikes R.J., Huygen F.J., van der Meijden P., Hop W.C., Hooijkaas H., Zijlstra F.J. Multiplex bead array assay for detection of 25 soluble cytokines in blister fluid of patients with complex regional pain syndrome type 1. Mediators Inflamm. 2006, 2006:28398.
10. Li N., Chen Y., He W., Yi T., Zhao D., Zhang C., Lin C.L., Todorov I., Kandeel F., Forman S., Zeng D. Anti-CD3 preconditioning separates GVL from GVHD via modulating host dendritic cell and donor T-cell migration in recipients conditioned with TBI. Blood 2009, 113:953-962.
11. Datta S., Biswas R., Novotny M., Pavicic P.G., Herjan T., Mandal P., Hamilton T.A. Tristetraprolin regulates CXCL1 (KC) mRNA stability. J. Immunol. 2008, 180:2545-2552.
12. Roche J.K., Keepers T.R., Gross L.K., Seaner R.M., Obrig T.G. CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation. Am. J. Pathol. 2007, 170:526-537.
13. Zhao F., Zhang Y., Wang H., Jin M., He S., Shi Y., Guo Y. Blockade of osteopontin reduces alloreactive CD8+ T cell-mediated graft-versus-host disease. Blood 2011, 117:1723-1733.
14. Albert M.H., Yu X.Z., Martin P.J., Anasetti C. Prevention of lethal acute GVHD with an agonistic CD28 antibody and rapamycin. Blood 2005, 105:1355-1361.
15. Blazar B.R., Levy R.B., Mak T.W., Panoskaltsis-Mortari A., Muta H., Jones M., Roskos M., Serody J.S., Yagita H., Podack E.R., Taylor P.A. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J. Immunol. 2004, 173:2933-2941.
16. Takeda M., Kobayashi M., Osaki T., Shirato I., Endou H. Staurosporine-induced apoptosis of immortalized mouse proximal tubule cells is modulated by BCL-2 expression level. Biochem. Mol. Biol. Int. 1997, 42:649-656.
17. Exley G.E., Tang C., McElhinny A.S., Warner C.M. Expression of caspase and BCL-2 apoptotic family members in mouse preimplantation embryos. Biol. Reprod. 1999, 61:231-239.
18. Satake A., Inoue T., Kubo S., Taniguchi Y., Imado T., Fujioka T., Horiuchi M., Xu Y., Ikegame K., Yoshihara S., Kaida K., Tamaki H., Okada M., Okamura H., Ogawa H. Separation of antileukemic effects from graft-versus-host disease in MHC-haploidentical murine bone marrow transplantation: participation of host immune cells. Int. J. Hematol. 2010, 91:485-497.
19. Das R., Komorowski R., Hessner M.J., Subramanian H., Huettner C.S., Cua D., Drobyski W.R. Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. Blood 2010, 115:5249-5258.
20. Ferrara J.L., Cooke K.R., Teshima T. The pathophysiology of acute graft-versus-host disease. Int. J. Hematol. 2003, 78:181-187.
21. Bleakley M., Riddell S.R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nat. Rev. Cancer 2004, 4:371-380.
22. Sadeghi B., Aghdami N., Hassan Z., Forouzanfar M., Rozell B., Abedi-Valugerdi M., Hassan M. GVHD after chemotherapy conditioning in allogeneic transplanted mice. Bone Marrow Transplant. 2008, 42:807-818.
23. Choi J., Ritchey J., Prior J.L., Holt M., Shannon W.D., Deych E., Piwnica-Worms D.R., DiPersio J.F. In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 2010, 116:129-139.
24. Pelus L.M., Fukuda S. Peripheral blood stem cell mobilization: the CXCR2 ligand GRObeta rapidly mobilizes hematopoietic stem cells with enhanced engraftment properties. Exp. Hematol. 2006, 34:1010-1020.
25. Robb R.J., Kreijveld E., Kuns R.D., Wilson Y.A., Olver S.D., Don A.L., Raffelt N.C., De Weerd N.A., Lineburg K.E., Varelias A., Markey K.A., Koyama M., Clouston A.D., Hertzog P.J., Macdonald K.P., Hill G.R. Type I-IFNs control GVHD and GVL responses after transplantation. Blood 2011, 118:3399-3409.
26. Matzer S.P., Rodel F., Strieter R.M., Rollinghoff M., Beuscher H.U. Constitutive expression of CXCL2/MIP-2 is restricted to a Gr-1high CD11b+ CD62Lhigh subset of bone marrow derived granulocytes. Int. Immunol. 2004, 16:1675-1683.
27. Joo S.Y., Cho K.A., Jung Y.J., Kim H.S., Park S.Y., Choi Y.B., Hong K.M., Woo S.Y., Seoh J.Y., Ryu K.H. Bioimaging for the monitoring of the in vivo distribution of infused mesenchymal stem cells in a mouse model of the graft-versus-host reaction. Cell Biol Int. 2011, 35:417-421.